Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for... ( ...)

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)

Date:3/30/2009

INSMED WILL CONTINUE TO MANAGE ALS EAP IN ITALY AND ALL IPLEX(TM) INITIATIVES IN THE U.S.

IDIS WILL HAVE RESPONSIBILITY FOR REST OF WORLD

RICHMOND, Va., March 30 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a biopharmaceutical company, today announced the signing of an agreement with IDIS, a private, UK-based company specializing in the management of medicines on a named patient basis, also known as expanded access programs (EAPs) or named patient programs (NPPs), to manage such programs for the investigational drug IPLEX(TM) worldwide, excluding the U.S. and Italy. An EAP or NPP provides drug developers across the world with a legal and ethical way to make medicines available, where appropriate, in response to requests made by physicians, when those medicines are not yet approved in their country.

Under the agreement, Insmed will continue to be responsible for the IPLEX(TM) EAP for Amyotrophic Lateral Sclerosis (ALS) in Italy, as well as all IPLEX(TM)-related activities in the U.S., while IDIS will assume responsibility for the management of IPLEX(TM) for all other EAPs/NPPs worldwide. IDIS is expected to initiate the management of these EAPs/NPPs during the second quarter of 2009, and will be responsible for prescription, product and pharmacovigilance management.

"This agreement reflects Insmed's deep commitment to providing IPLEX(TM) to patients that are suffering from debilitating diseases, such as Amyotrophic Lateral Sclerosis, and have no other medical options," said Dr. Geoffrey Allan, President and CEO of Insmed. "IDIS is a world leader in the management of named patient programs, has significant knowledge of the various unique healthcare systems internationally and is the ideal partner to ensure that patients have app
'/>"/>

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
2. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
3. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
4. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
5. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
6. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
7. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
8. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
9. Insmed to Seek Shareholder Approval for Reverse Split
10. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
11. Insmed to Present at Biosimilars 2008 Conference

Post Your Comments:

Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for...( ...)